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Angiogenesis is a key event in cancer progression and there-
fore a promising target in cancer treatment. Galectin-1, a-gal-
actoside binding lectin, is up-regulated in the endothelium of
tumors of different origin and has been shown to be the target
for anginex, a powerful anti-angiogenic peptidewith anti-tumor
activity. Here we show that when bound to anginex, galectin-1
binds various glycoproteins with hundred- to thousand-fold
higher affinity. Anginex also interacts with galectin-2, -7, -8N,
and -9N but not with galectin-3, -4, or -9C.
Anginex is a 33-mer cytokine-like artificial -peptide (the
sequence is given in supplemental Fig. S1) that inhibits endo-
thelial cell growth by specifically blocking adhesion and migra-
tion of activated endothelial cells leading to angiogenesis in
vitro and in vivo (1, 2). It inhibits microvessel formation but not
the larger, pre-existing vessels, pointing toward tumor specific-
ity (1). The profound anti-tumor effect is found both on tumor
growth and on established tumors in human xenograft mouse
models (2).
A two-hybrid screen using anginex as bait revealed the small
soluble lectin galectin-1 as a potential target, and the require-
ment of galectin-1 for the anti-angiogenic effect of anginex was
demonstrated using galectin-1-null mutant mice (3). This and
other studies on galectin-1 (4–6) suggested a rate-limiting role
of galectin-1 in tumor angiogenesis and indicated that anginex
interferes with the pro-angiogenic effect of galectin-1.
Galectin-1 consists of an 135-amino acid canonical galec-
tin carbohydrate recognition domain (CRD),2 which exists as a
mixture of monomers and dimers at physiological concentra-
tions (7, 8). Similar to other galectins, itsmain known biochem-
ical function is to bind -galactoside-containing glycoproteins
and cross-link them,whichmay result in various cellular signals
and consequent effects in immunity, inflammation, and cancer
(5, 9). Therefore we analyzed the effect of anginex on the car-
bohydrate binding activity of galectin-1, with the hypothesis
that it would act as an inhibitor. Surprisingly, we instead found
that anginexmay strongly enhance binding of galectin-1 to cer-
tain glycoconjugates.
EXPERIMENTAL PROCEDURES
Galectins, Glycoproteins, and Chemicals—Plasmids encod-
ing human galectin-1 (gift from Professor Richard Cummings,
Department of Biochemistry, Emory School of Medicine,
Atlanta, GA) and human galectin-1 C3S (gift from Dr. Jun
Hirabayashi, Research Center for Glycoscience, National Insti-
tute of Advanced Industrial Science and Technology (AIST),
Tsukuba, Japan) were expressed in Escherichia coli, and galec-
tins were purified by affinity chromatography on lactosyl-Sep-
harose and characterized as described before (8). The other
galectins were produced and purified in an analogous way as
described (10, 11). The oxidation-resistant mutant, galectin-1
C3S (galectin-1), was used inmost experiments to avoid having
to include -mercaptoethanol, which may perturb interacting
glycoprotein ligands, and was shown to have the same specific-
ity and affinity as wild type galectin-1 for a wide range of sac-
charides, probes, and glycoproteins (8, 12). Anginex and an
inactive control peptide (supplemental Fig. S1) (1, 13) and fluo-
rescein-tagged saccharide probes (supplemental Fig. S2) (8, 14)
were as described before. Asialofetuin (ASF), fetuin, haptoglo-
bin, and bovine serum albumin (BSA) were from Sigma. All
dilutions were prepared in 10% PBS buffer (12 mM NaCl, 7 mM
Na/K-phosphate, pH 7.2) because anginex stock solutions pre-
cipitate in high salt buffers; there was no evidence for any dif-
ference in affinity and specificity of galectin-1 for small saccha-
rides and probes between PBS and 10% PBS buffer. High
concentration of galectin-1 did not cause aggregation of ASF in
10% PBS buffer as it does in PBS, but the affinities were only
marginally lower in 10% PBS buffer (Kd 5 M as compared
with 3 M for ASF and 50 M as compared with 40 M for
fetuin).
Fluorescence Anisotropy—Affinities of probes and inhibitors
for galectin-1 were measured with fluorescence anisotropy
(FA) and calculated as described (8). Details are given in the
figure legends. All graphs were generated using Prism 4
(GraphPad Software Inc.).
RESULTS ANDDISCUSSION
The interaction between anginex and galectin-1 was investi-
gated using an FA assay (8, 15). In this assay, the interactions of
galectin-1 with fluorescein-tagged saccharide probes were
studied, as well as the perturbing effects of potential inhibitors/
modifiers. With a fixed concentration of a newly designed high
affinity tdga-probe (8) (supplemental Fig. S2A) and increasing
concentrations of galectin-1, the anisotropy rose from a value
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of 30 mA (A0  anisotropy of the free probe) to 170 mA
(Amax anisotropy of the galectin-probe complex) following a
curve of shape consistent with a 1:1 interaction and position
along x axis consistent with aKd0.4M.With the same probe
and galectin concentrations in the presence of 8 M anginex
(Fig. 1A), the curve shifted to the left, indicative of higher bind-
ing affinity (Kd 0.02 M), and Amax became higher (235
mA), indicative of more restricted mobility of the fluorescein
tag in the galectin-probe complex. With the LNT-probe (sup-
plemental Fig. S2B), there was no rise in the anisotropy with
increasing galectin-1 concentrations, due in part to lower affin-
ity (Kd 100 M) but also higher segmental mobility of the
fluorescein tag even in the galectin-probe complex, probably
because the galectin binds the terminal disaccharide (as indi-
cated in supplemental Fig. S2B and discussed in detail for other
galectins (10, 14)). In the presence of anginex, however, the
LNT-probe also gave a clear rise in anisotropy (to 120 mA)
and a curve consistent with a Kd 5 M (Fig. 1B). With both
probes, in the presence of anginex, the anisotropy values started
to drop when the galectin concentration started to exceed the
anginex concentration, most likely due to competition by ang-
inex-free galectin for the probe.
For a more detailed assessment of the affinity of the tdga-
probe for the galectin-1-anginex complex, fixed low concentra-
tions of galectin-1 (12 and 48 nM, not causing significant probe
binding by themselves) weremixed with 8M anginex and ana-
lyzed with a range of different concentrations of the probe.
From the anisotropy data, the concentrations of free and bound
probe were calculated and used to construct Scatchard plots.
These showed that the tdga-probe interacted with the galec-
tin-1-anginex complexwithKd25 nM (Fig. 1C), which is16-
fold higher affinity than for free galectin-1. The estimated con-
centration of these high affinity sites (from the x-intercept) was
39 nMwith 48 nM galectin-1 and 9.3 nMwith 12 nM galectin-1;
that is, about 80% of the available galectin would be in complex
with anginex. With 4 M anginex, the Scatchard plot was con-
sistent with 25 nM high affinity sites in 48 nM galectin-1
(50% of the added galectin), and in addition, lower affinity
sites were detected at the highest probe concentrations, prob-
ably due to free galectin-1. These data are consistent with the
affinity of anginex for immobilized galectin-1 in surface plas-
mon resonance (3).
To analyze the effect of anginex on non-labeled ligands, we
added these as inhibitors of the galectin-1-probe interaction as
described previously (8). In the first type of assay, a range of
concentrations of the glycoproteins ASF and fetuin was added
to fixed low concentrations of galectin-1 (0.25 M) and tdga-
probe (0.1 M) in the presence or absence of 8 M anginex,
anisotropy was measured, and the percentages of bound probe
and Kd values were calculated. In the absence of anginex, this
produced Kd values (assuming one binding site) of 5 M for
ASF and50 M for fetuin (Fig. 2, A and B), in agreement with
the previous results (Table 2 and supplemental Table S3 in Ref.
8). In the presence of 8Manginex, therewas a dramatic shift of
the inhibition curves to the left, indicative of much lower Kd
values, 10 nM for ASF and 20 nM for fetuin, an increase in
inhibitory potency of 500 and 2500 times, respectively.
To determine how many of the nine potential galectin-1
binding sites on ASF (16) become occupied, we used a second
type of assay, which previously identified one high affinity
galectin-1 binding site (Kd 3 M) using the tdga-probe and
another eight lower affinity sites using another low affinity
probe (8). In this assay type, a range of galectin concentrations
was mixed with fixed concentrations of tdga-probe (0.1 M),
glycoprotein (0 or 0.1M), and anginex (0 or 8M), the percent-
age of bound probe was calculated from the fluorescence ani-
sotropy (Fig. 2C), and the concentrations of free and glycopro-
tein-bound galectin-1 were calculated to construct Scatchard
plots (Fig. 2E). Inhibition by the glycoprotein is seen as a shift of
the binding curve to the right (Fig. 2C). Without anginex, there
was no inhibition (Fig. 2D) because the glycoprotein concentra-
tion used here (0.1 M) was much lower as compared with that
used previously (20–40 M) (8). However, in 8 M anginex,
there was a clear shift of the curves for both glycoproteins (Fig.
2C). BSA, which does not bind galectin-1, did not give a curve
shift even in the presence of anginex (Fig. 2C, inset), which
validates the assay. The Scatchard plots indicated about 1.5
binding sites per molecule for ASF and about 1 for fetuin, sim-
ilar to that foundwith the tdga-probe in the absence of anginex
(8), but with several hundred- to thousand-fold higher affinities
(Kd 15 nM). We also analyzed the interaction of galectin-1
with haptoglobin, a naturally occurring human serum glyco-
protein (Fig. 2F). A clear shift of the binding curve was found in
FIGURE 1. Effect of anginex on the interaction of galectin-1 with fluores-
cein-labeledsaccharideprobes.AandB, a rangeofdifferent concentrations
of galectin-1was added to amicrotiter plate together with a fixed concentra-
tion (0.1M) of tdga-probe (A) or LNT-probe (B) in 8M anginex or 10% PBS
buffer, and fluorescence anisotropy was measured using a PolarStar plate
reader. Binding curves were generated by plotting anisotropy against
increasing concentrations of galectin-1. C and D, fixed low concentrations of
galectin-1 (12 or 48 nM) were mixed with a range of concentrations of tdga-
probe in the presence of 8 M (C) or 4 M (D) anginex. Fractions of bound
probe were calculated ((A  A0)/(Amax  A0)), and from this, fractions of
freeprobe (totalbound)werecalculated. Finally, bound tdga-probewasplot-
ted against bound/free tdga-probe to construct Scatchard plots. In D, linear
regressionwasmadewith a fixed Kd 25 nM, as found for 8M anginex. Graphs
weremade using Prism 4 (GraphPad Software Inc.). The structures of the probes
are shown in supplemental Fig. S2.
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the presence of anginex but not in its absence (inset), suggesting
enhanced affinity of galectin-1 also for this glycoprotein in the
presence of anginex. In contrast, the inhibitory potencies of
small saccharides, Gal1-4Glc-O-Me and Gal1-4GlcNAc-
O-Me, known to bind galectin-1 (8), were not enhanced in the
presence of anginex (not shown).
Anginex was selected based on its anti-angiogenic activity
from a panel of 30 different designed peptides with small
variations in sequence (1). From this panel of peptides,pep-28
(supplemental Fig. S1) has been shown to have a similar struc-
ture as anginex (13) but to be biologically inactive, and hence, it
has been used as a negative control (1, 2). In the FA assay, this
peptide also had no effect either when it was analyzed with
galectin-1 and the two probes, at concentrations where the
addition of anginex would result in the maximal increase in
fluorescence anisotropy (Fig. 3A), or when screened with a
range of galectin-1 concentrations (Fig. 3B), as done with ang-
inex in Fig. 1A. This shows that the interaction of anginex with
galectin-1 in the FA assay is specific and correlates with its
biological activity. The concentrations (low M) of anginex
required for the effects in the FA assay described above are also
in the same range as those required for its biological effects (1).
We finally assessed the effect of anginex on othermembers of
the galectin family. Anginex was added to different galectins, at
fixed concentrations with different probes selected based on
our extensive use of the FA assay, to test galectin inhibitors (11).
Galectin-2 and -7 and the N-terminal CRDs of galectin-8 and
FIGURE 2. Effect of anginex on galectin-1 interaction with glycoproteins
ASF, fetuin, and haptoglobin. A and B, increasing concentrations of ASF (A)
or fetuin (B)weremixedwith0.1M tdga-probe and0.25Mgalectin-1 in the
presence or absence of 8 M anginex, and anisotropy was measured. The
percentage of bound probe was calculated as 100 (A A0)/(Ano inhibitor
A0) and plotted against inhibitor concentration. The inhibition curve goes
down to 0% bound probe for ASF because after the anginex-galectin-1 com-
plex has been saturated, the ASF concentration (low M) is also enough to
inhibit remaining free galectin-1 (A). However, this is not the case for fetuin,
where a residual of about 10–20% bound probe is observed even at higher
fetuin concentrations, which may be due to the fact that fetuin is a poor
inhibitor for free galectin-1. C and D, increasing concentrations of galectin-1
wereadded toa fixedconcentrationof tdga-probe (0.1M) and0.1MASFor
fetuin in the presence of 8 M anginex (C) or without anginex (D). The per-
centage of bound tdga-probewas calculated and plotted against increasing
concentration of galectin-1. BSA (C, inset) was run as a non-binding control.
E, the percentage of bound probe was used to estimate the concentration of
free galectin-1 in the presence of glycoprotein using the values in its absence
as a standard curve, and then the concentration of glycoprotein-bound
galectin-1 was calculated (total free probe-bound), and Scatchard plots
were constructed as described previously (Fig. 6 in Ref. 8). Data points in
parenthesiswere not included in the linear regression calculation. F, same as
in C, butwith 0.1Mhaptoglobin as inhibitor andwithout anginex (as inD) as
inset.
FIGURE 3. Effect of a control peptide, pep-28, and the effect of anginex
on other galectins. A, 0.1M tdga-probe or LNT-probewasmixed with 0.1
or 3 M galectin-1, respectively, in the presence of 8M anginex, 8 M pep-
28, or no peptide, and anisotropywasmeasured. Free probes (A0) were run in
parallel. Increased anisotropy (Apeptide  Ano peptide) (y axis) was calculated
with Apeptide A A0 in anginex or pep-28 and Ano peptide A A0 in the
absence of peptide. The amino acid sequences of anginex and pep-28 are
shown in supplemental Fig. S1.B, a rangeof different concentrations of galec-
tin-1 was analyzed with a fixed concentration (0.1 M) of tdga-probe in the
samewayas in Fig. 1Abut in thepresenceor absenceof 8Mpep-28 instead
of anginex. C, different combinations of probe (0.1 M) and galectin (tdga-
probe: 0.5 M galectin-1, 10 M galectin-2, 3 M galectin-4N, 2 M galectin-
9C;A-tetra-saccharide-probe (14): 1Mgalectin-3, 0.5Mgalectin-4, 0.5M
galectin-4C; LNnT-probe (14): 2 M galectin-7; LNnT-probe (23): 0.4 M
galectin-8N, 0.4 M galectin-8S, and 1 M galectin-9N) were analyzed in the
presence or absence of 16 M anginex. The different probe-galectin combi-
nations and concentrations were chosen to ensure binding in the absence of
anginex. 16 M anginex was used instead of 8 M to exceed the highest
galectin concentration (10 M for galectin-2). Free probes were measured in
parallel, and increased anisotropy (Aanginex  Ano anginex) (y axis) was calcu-
lated with Aanginex  A  A0 in anginex and Ano anginex  A  A0 without
anginex. Error bars in A and C indicate S.E.
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-9, but not galectin-3 and -4 and the C-terminal CRD of galec-
tin-9, showed an increased anisotropy, indicating interaction
with anginex (Fig. 3C).
In summary, we have found that the synthetic anti-angio-
genic peptide anginex dramatically enhances the affinity of
galectin-1 for certain ligands, including biologically relevant
glycoproteins. In fact, this apparently monovalent interaction
has among the highest affinities (Kd low nM) ever reported for a
lectin. To elucidate the precise mechanism of this and its con-
sequences in cellular systems will require further study.
Because anginex tends to form dimers and larger aggregates
(3, 13), the mechanism for its effect may entail increased cross-
linking of galectin-1. However, more specific conformational
modification of a single CRD is also possible.
One possible general explanation for the biological effects of
anginex may be due to shifts of galectin-1 receptor binding
equilibria.Many of the proposed regulatory effects of galectin-1
appear to involve reversible binding to receptors with affinities
in the lowM range (17–19), perhaps with reversible formation
and dissolution of cross-linked lattices (4, 9, 20, 21). If affinity
for certain ligands were increased hundred- to thousand-fold,
as seen here, such equilibria would be dramatically altered.
The anginex effect on galectin-1 may also mimic a normal
function; it is hard to believe that an artificial peptide can show
such dramatic effects without speculating that there is a natural
counterpart in vivo. This also becomes an intriguing thought
because galectin-1 in some cases showedbiological effects at nM
concentrations (e.g. Fig. 3 in Ref. 6) or surprisingly little was
needed to rescue the null phenotype inmice in vivo (22) despite
the fact that, as mentioned above, most known ligands have
affinities in theMrange. There aremany text book caseswhere
strong binding activity of one protein is induced by another
protein or smallermolecule, but it has not been foundbefore for
the carbohydrate binding activity of galectins, or perhaps not
even lectins in general (except for cations). The fluorescence
anisotropy assay used here provides a simple screeningmethod to
find natural modifiers of galectin ligand binding and also to select
designed peptides with similar effects, for example, in the search
for new improved versions of anginex as anti-cancer agents.
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